AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceHealth Care
Bone MarrowLeukemia, Lymphocytic, Chronic, B-CellLeukemia, LymphoidBone Marrow CellsPrecursor Cell Lymphoblastic Leukemia-LymphomaBone Marrow TransplantationLeukemiaBone and BonesLeukemia, Myeloid, AcuteLeukemia, B-CellLeukemia, Myelogenous, Chronic, BCR-ABL PositiveBone Marrow ExaminationHematopoietic Stem CellsLeukemic InfiltrationBone Marrow DiseasesBone RemodelingB-LymphocytesAsparaginaseLeukemia, T-CellBone Marrow NeoplasmsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaVidarabineMethotrexateT-Lymphocytes, CytotoxicAntineoplastic AgentsCytarabineLeukemia, Biphenotypic, AcuteRemission, SpontaneousRemission InductionVincristineLeukemia, ExperimentalFlow CytometryGene Expression Regulation, LeukemicTransplantation, HomologousLymphocytes, NullLymphomaBone DensityImmunoglobulin Heavy ChainsT-Lymphocytes6-MercaptopurineLeukemia-Lymphoma, Adult T-CellAntineoplastic Combined Chemotherapy ProtocolsPrognosisReceptors, Antigen, B-CellLymphocytesBurkitt LymphomaAntibodies, MonoclonalCyclophosphamideLeukemia, MyeloidBone ResorptionKaryotypingTumor Cells, CulturedLeukemia, Hairy CellBone Marrow PurgingRosette FormationZAP-70 Protein-Tyrosine KinaseChlorambucilCell DifferentiationHematopoiesisTime FactorsAcute DiseaseImmunophenotypingMice, Inbred C57BLPhiladelphia ChromosomeRecurrenceDNA, NeoplasmCells, CulturedAntigens, NeoplasmBlast CrisisChromosomes, Human, 6-12 and XChromosome AberrationsTreatment OutcomeAntigens, CD38AnisocoriaBone NeoplasmsTranslocation, GeneticAntigens, SurfaceDNA NucleotidylexotransferaseColony-Forming Units AssayFusion Proteins, bcr-ablLeukemia Virus, MurineBase SequenceCell LineAntigens, CD5CladribineApoptosisCorneal PerforationMolecular Sequence DataAntigens, CDNeoplasm ProteinsPolymerase Chain ReactionSurvival AnalysisBone DevelopmentDrug Resistance, NeoplasmDaunorubicinTransplantation, AutologousCell Line, TumorGraft vs Host DiseaseImmunoglobulin Variable RegionNeprilysin
LymphoblasticChemotherapyLymphomaLymphomasMyelogenous leukemiaMultiple myelomaTransplantTransplantationLymphocytesTargeted cellsPrognosisPeripheralPatient with acute lymphocyChronic leukemiasFlow cytometryMalignantMyelodysplasticLeukemicChildhood acute myeloidPatients with chronic lymphocyCancersMalignanciesSeverely suppressOncologySevereDiagnosisTumorMutationsAccumulationImmatureLeukocyteMaturationLeukaemiaProliferationBlastsStem cellsLymphFibrosisClonalSuppressionLymphoblastsLymphocyteTherapeutic targetsOccurOutcomesTransplantsReceptorFludarabinePancytopeniaLIVERAdult
Lymphoblastic21
  • In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of CAR-T cells. (nature.com)
  • B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of childhood cancer and mostly derives from immature B cells that carry the cell surface antigen CD19 (ref. 1 ). (nature.com)
  • This blood cancer is divided into several groups based on whether the leukemia is fast growing (acute leukemias) or slower growing (chronic leukemias), and whether it starts in myeloid cells (myeloid or myelogenous leukemias) or lymphoid cells (lymphoblastic or lymphocytic leukemias). (lls.org)
  • The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and solid tumor triple negative breast cancer (TNBC) malignancies. (moffitt.org)
  • CAR-T cells, which incorporate an antibody-derived extracellular receptor and T cell derived intracellular signaling domains, have shown convincing outcomes in certain types of leukemia and lymphoma, including commercial licensure of CD19 CAR-Ts for the treatment of relapsed/ refractory large B cell lymphoma and acute lymphoblastic leukemia. (bdbiosciences.com)
  • The technique has also shown preliminarily promising outcomes in B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma and multiple myeloma in clinical trials targeting CD19, CD20, CD22, CD30 and B-cell maturation antigen (BCMA), with many more under investigation. (bdbiosciences.com)
  • Acute lymphoblastic leukemia (acute lymphocytic leukemia, ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. (medscape.com)
  • The image below shows pre-B-cell lymphoblastic leukemia/lymphoma (B-ALL). (medscape.com)
  • Acute lymphoblastic leukemia (ALL): Bone marrow shows proliferation of large and heterogeneous lymphoblasts consistent with pre-B-cell ALL (French-American-British L2 morphology). (medscape.com)
  • See the Childhood Acute Lymphoblastic Leukemia: Diagnosis, Management, and Complications slideshow to help recognize and treat this disease and its associated complications. (medscape.com)
  • See also Pediatric Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia (AML) . (medscape.com)
  • Lymphoblastic leukemias/lymphomas are neoplasms of precursor T cells and B cells or lymphoblasts. (medscape.com)
  • however, because lymphoblastic lymphoma and acute lymphoblastic leukemia (ALL) are known to represent the same disease entity, the World Health Organization (WHO) classification has unified these entities as precursor B-cell and T-cell lymphoblastic leukemia/lymphoma. (medscape.com)
  • 20% lymphoblasts in marrow), a diagnosis of lymphoblastic lymphoma is made. (medscape.com)
  • Many investigators have suggested that both lymphoblastic lymphoma and acute lymphoblastic leukemia (ALL) may be part of one clinical spectrum of a single malignant lymphoproliferative disorder . (medscape.com)
  • Although several subtypes of T-cell lymphoblastic leukemia/lymphoma exist, early T-cell precursor lymphoblastic leukemia (ETP-ALL) is the only subtype recognized as an entity in the revised 2016 WHO tumor classification. (medscape.com)
  • [ 1 ] ETP-ALL frequently has mutations in RUNX1 and/or ETV6 in addition to genes that are more commonly associated with myeloid neoplasms and are otherwise rare in T-cell lymphoblastic leukemia/lymphoma (such as FLT3 , IDH1/2 , TET2 , and DNMT3A mutations). (medscape.com)
  • Non-ETP subtypes of T-cell lymphoblastic leukemia/lymphoma, in contrast, are associated with activating NOTCH1 mutations in over half of all patients and an additional 10% to 15% of cases have FBXW7 mutations, which also result in increased NOTCH signaling. (medscape.com)
  • T-lymphoblastic lymphoma (T-LBL) accounts for 25-30% of childhood NHL and is closely related to T-lymphoblastic leukemia (T-ALL). (medscape.com)
  • The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related variations (0.53 at 45-54 years, ∼1.0 at 55-74 years and 1.45 at 75-99 years). (medscape.com)
  • Population-based attributes for Social Exclusion Index (SEI) and household size may be useful surrogate markers of early exposure to childhood infections, which has been found to decrease the risk of acute lymphoblastic leukemia (ALL). (medscape.com)
Chemotherapy6
  • During his postdoctorial research at Memorial Sloan-Kettering Cancer Center, he worked with a group that demonstrated that a neutrophil differentiation factor (G-CSF) therapy ameliorated the neutropenia associated with cytotoxic chemotherapy and accelerated neutrophil recovery following bone marrow transplantation. (aacc.org)
  • [ 10 ] More recently, it was described in patients with other forms of severe immunodeficiency including those associated with chemotherapy, organ transplant, and leukemia. (medscape.com)
  • However, relapsed ALL remains a leading cause of childhood death despite intensive cytotoxic chemotherapy often including allogeneic bone marrow transplantation. (nature.com)
  • Nearly every breakthrough in cancer treatment has emerged from our support of leukemia research, from chemotherapy to groundbreaking CAR T-cell immunotherapy. (lls.org)
  • The five-year survival rate for a child with leukemia 50 years ago was a dismal 3%, but with the advent of combination chemotherapy as standard of care in the 1960s, increasing understanding of the disease, and more recent discoveries of novel therapeutics, cures are now possible in children. (lls.org)
  • No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy. (knowcancer.com)
Lymphoma11
  • Malignant disorders associated with secondary HLH include T-cell lymphoma, B-cell lymphoma, acute lymphocytic leukemia, acute myeloid leukemia, and myelodysplastic syndrome. (wikipedia.org)
  • The need for new treatments for AML remains urgent, which is why The Leukemia & Lymphoma Society (LLS) has invested approximately one quarter of its research doll. (lls.org)
  • Over the past 10 years, The Leukemia & Lymphoma Society (LLS) has invested more than $52 million to accelerate pioneering research in chronic lymphocytic leukemia (CLL), a blood cancer characterized by the development of too many white blood cells called lymphocytes. (lls.org)
  • The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. (lls.org)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)
  • In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML). (hindawi.com)
  • Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000. (knowcancer.com)
  • Malignant lymphoma - small lymphocytic, Nodular or diffuse: (single agent) 40 to 50 mg/kg IV in divided doses over 2 to 5 days OR 10 to 15 mg/kg IV every 7 to 10 days OR 3 to 5 mg/kg IV twice weekly. (wikidoc.org)
  • Malignant lymphoma - small lymphocytic, Nodular or diffuse: (single agent) oral cyclophosphamide is usually administered at dosages in the range of 1 to 5 mg/kg/day for both initial and maintenance dosing. (wikidoc.org)
  • LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. (nih.gov)
Lymphomas4
  • Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. (nih.gov)
  • thus, tumors with a high cell turnover are most susceptible (certain leukemias and lymphomas, small proliferating tumors, "recruited" tumor cells, and micrometastases). (doctorlib.info)
  • Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
  • Methotrexate, a folic acid analog/antimetabolite, can be curative for women with choriocarcinoma and is also useful for non-Hodgkin lymphomas and acute lymphocytic leukemias (ALLs) in children. (medquizzes.net)
Myelogenous leukemia6
Multiple myeloma1
  • Multiple myeloma (MM) is closely associated with bone destruction. (oncotarget.com)
Transplant3
  • Later, many cases were reported in heart, kidney, and bone marrow transplant recipients and in patients with hematological malignancies. (medscape.com)
  • Historical transplants used a matched donor's peripheral blood or bone marrow to transplant to a patient. (biologynews.net)
  • Prior allogeneic hematopoietic stem cell transplant (HSCT) or donor lymphocyte infusion within 6 months prior to enrollment, current acute graft versus host disease grade 2-4 by Glucksberg criteria or severity B-D by by International Bone Marrow Transplant Registry (IBMTR) index or history of severe (grade 3-4) acute graft versus host disease. (moffitt.org)
Transplantation3
  • However, Zweidler-McKay and co-senior investigator Elizabeth Shpall, M.D., professor in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy, have found a novel process to increase NK cells in cord blood more than 30-fold, generating more than 150 million NK cells from one cord blood unit while maintaining their activation to find and kill acute leukemia cells. (biologynews.net)
  • letters to the editor: bone marrow transplantation and leukemic transformation of transplanted cells]. (liverpool.ac.uk)
  • Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. (cdc.gov)
Lymphocytes5
  • Cytotoxic T lymphocytes cannot eliminate EBV from the body, but they are essential in maintaining the latent state of the infection. (medscape.com)
  • In states of immune dysfunction in which the number of EBV-specific cytotoxic T lymphocytes is decreased, there is an increase in the number of circulating EBV-infected B cells. (medscape.com)
  • Chronic lymphocytic leukemia (CLL) is characterized by progressive accumulation of phenotypically mature malignant B lymphocytes. (msdmanuals.com)
  • Lymphocytes initially accumulate in the bone marrow and then spread to lymph nodes and other lymphoid tissues, eventually inducing splenomegaly, hepatomegaly, and systemic symptoms such as fatigue, fever, night sweats, early satiety, and unintentional weight loss. (msdmanuals.com)
  • Chronic lymphocytic leukemia (CLL) is a B-cell hematological malignancy characterized by the clonal expansion and accumulation of morphologically mature B-lymphocytes in peripheral blood, bone marrow, and secondary lymphoid tissues. (oncotarget.com)
Targeted cells1
  • The most common and best studied causes of Primary HLH are loss of function, (i.e. inactivating) mutations in genes that code for proteins cytotoxic T cells and NK cells use to kill targeted cells, such as those infected with pathogens like the Epstein-Barr virus (EBV) or the Dengue virus. (wikipedia.org)
Prognosis3
Peripheral1
Patient with acute lymphocy1
  • [ 3 ] The first case in an HIV-negative patient was reported in 1999 in a 56-year-old patient with acute lymphocytic leukemia. (medscape.com)
Chronic leukemias1
  • Unlike acute leukemias (which have a sudden onset, progress rapidly, and, if untreated, can be fatal in as little as two months from the onset of symptoms), chronic leukemias are indolent. (pocketdrugguide.com)
Flow cytometry1
Malignant1
Myelodysplastic3
  • Paired bone marrow samples that were obtained from two cohorts of patients with myelodysplastic syndrome before and after treatment with a hypomethylating agent were used to explore the relationships among changes in SALL4 expression, treatment response, and clinical outcome. (bvsalud.org)
  • Spliceosome mutations are common in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), but the oncogenic changes due to these mutations have not been identified. (cancer-genetics.org)
  • The majority of patients rechallenged with fludarabine phosphate developed recurrence in the hemolytic process.In post-marketing experience, cases of myelodysplastic syndrome and acute myeloid leukemia, mainly associated with prior, concomitant or subsequent treatment with alkylating agents, topoisomerase inhibitors, or irradiation have been reported. (drugcentral.org)
Leukemic2
  • Acute myeloid leukemia (AML) is generally regarded as a stem cell disease, and it originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity [ 1 , 2 ]. (researchsquare.com)
  • in other words, the leukemic mutations may affect any stage of hematopoietic differentiation, and the type of leukemia can be characterized by the type of affected cell. (pocketdrugguide.com)
Childhood acute myeloid1
  • Patients with childhood acute myeloid leukemia (AML) with complex karyotypes (CKs) have a dismal outcome. (cancerindex.org)
Patients with chronic lymphocy2
  • This persistence signature was also detected in two adult patients with chronic lymphocytic leukemia with decade-long remissions who received a different CD19 CAR-T cell product. (nature.com)
  • The apparent volume of distribution averaged 0.31 L/kg following a single 0.2 mg/kg oral dose of chlorambucil in 11 cancer patients with chronic lymphocytic leukemia. (nih.gov)
Cancers3
  • Leukemia is also the most common cancer in general in children and teens, accounting for almost one out of three cancers. (lls.org)
  • Aberrant activation of lymphoid enhancer-binding factor-1 (LEF1) has been identified in several cancers, including chronic lymphocytic leukemia (CLL). (oncotarget.com)
  • Leukemias are cancers of the hematopoietic (blood-producing) system. (pocketdrugguide.com)
Malignancies3
  • Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported responses in lymphoid malignancies but larger studies are needed. (knowcancer.com)
  • Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are myeloid blood cell malignancies that show great heterogeneity. (biomedcentral.com)
  • 6] Case reports have described AN associated with hematologic malignancies, including acute myeloid leukemia, and even benign gastrointestinal neoplasms. (medscape.com)
Severely suppress2
Oncology1
  • Patrick Zweidler-McKay, M.D., Ph.D., assistant professor of pediatrics from the Children's Cancer Hospital at M. D. Anderson, has shown an effective method for expanding the number of NK cells from a single cord blood unit while retaining the cells' anti-leukemia effects, as presented at the American Society of Pediatric Hematology/Oncology annual conference on May 16. (biologynews.net)
Severe5
  • When used at high doses in doseranging studies in patients with acute leukemia , FLUDARA (fludarabine) FOR INJECTION was associated with severe neurologic effects, including blindness, coma, and death. (rxlist.com)
  • Similar severe central nervous system toxicity, including coma, seizures, agitation and confusion, has been reported in patients treated at doses in the range of the dose recommended for chronic lymphocytic leukemia. (rxlist.com)
  • Symptoms may vary from chronic symptoms like retinopathy, CKD, hematopoietic ulcers to severe acute complaints like "Sickle Cell Crisis" triggered by dehydration, infections, acidosis and other obscure reasons. (atomictherapy.org)
  • Foundations of the severe acute respiratory syndrome preparedness and response plan for healthcare facilities. (cdc.gov)
  • Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. (cdc.gov)
Diagnosis3
  • Therefore, VSTM1-v1 might represent an important myeloid leukocyte differentiation antigen and provide a potential target for the diagnosis and treatment of leukemia. (biomedcentral.com)
  • Conversely, a diagnosis of ALL generally requires at least 20% lymphoblasts in marrow. (medscape.com)
  • The immune landscape in CML bone marrow is immunosuppressed at diagnosis and can be partially reset with TKI treatment. (helsinki.fi)
Tumor2
  • Like other cytotoxic drugs, methotrexate may induce "tumor lysis syndrome" in patients with rapidly growing tumors. (nih.gov)
  • Binding of a tumor antigen via the scFv activates the T cell in a major histocompatibility-independent manner which leads to a cytotoxic response [ 3 ]. (nature.com)
Mutations3
  • Emergence of LSC is dependent on individual or combined genetic mutations that broadly determine the cellular affiliation of the leukemia, and permit or impose ectopic self-renewal and a restricted differentiation potential into what constitutes the proliferative bulk of the leukemia ( 5 , 6 ). (frontiersin.org)
  • FHL is an autosomal recessive disease caused by several mutations in the NK/T-cell cytotoxic pathway. (medscape.com)
  • [ 10 ] Other genetic causes involve mutations in genes regulating the packaging, transport, or release of cytotoxic granules. (medscape.com)
Accumulation1
  • As a visiting scientist at the University in Bergen in Norway, Dr. Warren developed a number of new assays, including a unique method for the determination of the levels of cytotoxic nucleotide accumulation into the leukocyte DNA of acute lymphocytic leukemia patients receiving 6-mercaptopurine maintenance therapy. (aacc.org)
Immature1
  • Acute myeloid leukemia (AML) is an aggressive, rapidly-progressing disease in which the immature blood cells do not develop properly and grow uncontrollably. (lls.org)
Leukocyte2
  • Herein, we report a potential leukocyte differentiation antigen gene VSTM1 ( V-set and transmembrane domain-containing 1 ) that was downregulated in bone marrow cells from leukemia patients and exhibited a higher degree of promoter methylation. (biomedcentral.com)
  • VSTM1 ( V-set and transmembrane domain-containing 1 ) encodes a potential leukocyte differentiation antigen that is highly expressed in myeloid cells, but silenced in multiple leukemia cell lines [ 1 ]. (biomedcentral.com)
Maturation2
  • Once migrated to the bone marrow, MM cells unbalance bone formation and resorption via the recruitment and maturation of osteoclast precursors. (oncotarget.com)
  • Leukemia occurs when a genetic mutation arises in a single cell that interferes with the normal maturation and differentiation of developing leukocytes. (pocketdrugguide.com)
Leukaemia1
  • Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. (bvsalud.org)
Proliferation2
  • The Notch pathway plays a key role in different types of cancer and drives several biological processes relevant in MM, including cell localization within the bone marrow, proliferation, survival and pharmacological resistance. (oncotarget.com)
  • The word leukemia derives from the Latin word for white blood and refers to the proliferation of white blood cells (leukocytes) in people with this disease. (pocketdrugguide.com)
Blasts1
  • These NK cells demonstrate significant cytotoxic activity against human AML and ALL cell lines and patient leukemia blasts. (biologynews.net)
Stem cells6
Lymph1
  • Side effects of Cytoxan include vulnerability to infections, the development of a secondary cancer, typically of the bladder, lymph nodes, or bone marrow. (canadianfpharmacy.com)
Fibrosis2
  • The main adverse responses to MTX, regardless of the purpose for which it is given, include bone marrow suppression, pulmonary damage (infiltrates, fibrosis), stomatitis, and lesions elsewhere in the GI tract. (medquizzes.net)
  • Bone marrow fibrosis occurred in one CLL patient treated with fludarabine phosphate.Several instances of trilineage bone marrow hypoplasia or aplasia resulting in pancytopenia, sometimes resulting in death, have been reported in post-marketing surveillance. (drugcentral.org)
Clonal2
Suppression1
  • When low MTX doses are used leucovorin may be withheld until and unless blood counts show evidence of MTX-induced bone marrow suppression. (medquizzes.net)
Lymphoblasts3
  • These aberrant lymphoblasts proliferate, reducing the number of the normal marrow elements that produce other blood cell lines (red blood cells, platelets, and neutrophils). (medscape.com)
  • The lymphoblasts infiltrate nodal structures or extranodal structures and is commonly associated with large mediastinal masses with a high predilection for disseminating to bone marrow and the central nervous system (CNS). (medscape.com)
  • In 30-50% of patients, the lymphoblasts infiltrate bone marrow, causing ineffective hematopoiesis. (medscape.com)
Lymphocyte1
  • The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
Therapeutic targets2
  • We discuss the value of lncRNAs as putative diagnostic, prognostic and therapeutic targets in myeloid leukemias and indicate novel directions in this exciting research field. (frontiersin.org)
  • These results make the Jagged ligands new promising therapeutic targets in MM to contrast bone disease and the associated co-morbidities. (oncotarget.com)
Occur2
  • Methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis, is a potentially dangerous lesion, which may occur acutely at any time during therapy and has been reported at low doses. (nih.gov)
  • HLH has been traditionally divided into a primary form, which typically manifests in children with documented genetic abnormalities of the cytotoxic function of NK cells and T cells, and a secondary form that tends to occur at older ages in the setting of an associated condition, such as infection and malignancy, without an identifiable genetic abnormality. (medscape.com)
Outcomes1
  • Outcomes for the treatment of chronic myeloid leukemia (CML) have dramatically improved over the past 50 years. (lls.org)
Transplants1
  • While the ten year survival rates were less than 20% with the use of cytotoxic agents in the 1970's, and improved to 50% with bone marrow transplants, the biggest improvements occurred within the last 20 years after the approval of an oral therapy, known as imatinib. (lls.org)
Receptor2
  • In this study, we systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. (nature.com)
  • In this issue of Blood , Brentjens and colleagues report on the feasibility, tolerability, and persistence of autologous CD19-directed chimeric antigen receptor (CAR) T cells in patients with relapsed chronic lymphocytic leukemia (CLL) and B-cell acute lymphocytic leukemia (B-ALL). (ashpublications.org)
Fludarabine1
  • Fludara (fludarabine) is a cancer medication used to treat B-cell chronic lymphocytic leukemia (CLL). (rxlist.com)
Pancytopenia1
LIVER1
  • While erythrocytes in the fetus are initially produced in the yolk sac then the liver, the bone marrow eventually becomes the main site of production. (lecturio.com)
Adult2
  • An exception was long-lived CAR-T cells in two adult individuals with a different cancer-chronic lymphocytic leukemia (CLL)-in whom anti-CD19 CAR-T cells have persisted for almost a decade thus far 7 . (nature.com)
  • Characterization of immune cell contexture in adult ALL bone marrow microenvironment. (helsinki.fi)